Cerus Corporation sees growth with INTERCEPT RBCs trial success By Investing.comMay 4, 20240 Cerus Corporation (NASDAQ:) has announced positive outcomes from its Phase 3 ReCePI clinical trial for INTERCEPT red blood cells (RBCs),…